Chronic widespread pain (CWP) is common among minoritized adults with clinical obesity, and effective symptom management remains challenging. Weight loss achieved through bariatric surgery is frequently recommended to reduce musculoskeletal pain, but observed pain trajectories after surgery vary substantially. The impact of weight loss on movement-evoked pain (MEP) and the biobehavioral mechanisms that may link weight reduction to pain changes are not well characterized. This protocol defines a prospective observational approach to systematically profile pain and related biosignatures in this patient population through the early postoperative period.
The primary aims are to quantify longitudinal changes in pain at rest (PAR) and movement-evoked pain (MEP) up to 6 months after bariatric surgery, and to evaluate whether pain modulatory mechanisms, joint motion, and mechanical loading biosignatures mediate the relationship between weight loss and pain change. Secondary objectives include collecting comprehensive patient-reported outcomes and functional measures to characterize changes across clinical and experimental domains.
This is a prospective, longitudinal, observational cohort study enrolling 60 individuals undergoing bariatric surgery for weight loss. The cohort is described as minoritized adults with clinical obesity and coexisting chronic widespread pain. Participants will be assessed at baseline (pre-surgery) and at 3 and 6 months post-surgery. No interventional treatments are assigned as part of the study beyond the clinical care participants receive for bariatric surgery.
Participants will complete a series of standardized assessments at each study visit. These include:
Assessments are scheduled at baseline, 3 months, and 6 months after surgery to capture early and intermediate postoperative trajectories.
The protocol specifies both clinical and experimental approaches to characterize pain modulatory mechanisms. Although the preprint does not provide itemized measurement instruments in the abstract, it indicates the use of experimental pain testing and functional assessments alongside questionnaires and anthropometrics. These combined modalities are intended to establish biobehavioral biosignatures that may explain inter-individual differences in pain response after weight loss.
A standardized movement testing battery will be implemented to quantify joint motion and mechanical loading during defined tasks. Motion will be recorded with camera-based motion capture systems. The data from motion capture are intended to provide objective measures of biomechanical change that may mediate alterations in movement-evoked pain following weight loss.
Primary analyses will use generalized linear mixed models to assess the significance of changes in PAR, MEP, and all patient-reported outcome measures across time. In these models, time will be treated as a fixed effect and intra-individual repeated measures will be modeled as random effects. Reduced models will be employed to test specific hypotheses about effects over time and potential mediators. The preprint abstract does not provide detailed specifications for covariates, power calculations, or model parameterization; those details were not reported in the source abstract.
This observational study is registered on ClinicalTrials.gov (NCT0675386). Institutional review board approvals have been obtained from NYU Langone Health (IRB# i21-01652) and the New York City Health + Hospitals/Bellevue Research Office (Bellevue Study ID: STUDY00003739). The authors confirm that participant consent procedures and institutional approvals were completed and archived. The manuscript emphasizes that the preprint has not been peer reviewed and should not be used to guide clinical practice. Planned dissemination includes publication in peer-reviewed journals and presentations at national and international conferences and community events.
Funding for the study is reported from several sources: the National Institute of Arthritis and Musculoskeletal and Skin Diseases (K23AR080846), the National Heart Lung and Blood Institute (training and career development awards referenced), and the National Center for Advancing Translational Sciences (UL1TR001445). The preprint lists a competing interest for Dr. Melanie Jay: receipt of Veterans Affairs funding outside this work, advisory board membership with Bonus Health and Onsera Health, and consulting fees from Novo Nordisk and AbbVie outside the present study.
At the time of posting, no datasets had been generated or analyzed. The authors state that all relevant data from the study will be made available upon study completion. The preprint includes links to supplementary material and data/code resources where applicable.
All descriptions above are derived from the study protocol abstract and associated declarations in the medRxiv preprint. The abstract does not report specific measurement instruments, sample size justification beyond the planned N=60, detailed inclusion/exclusion criteria, or the exact experimental pain testing protocols; those details were not reported in the source abstract and would be expected to appear in the full protocol or supplementary material.